The Xpert GI Panel identifies pathogens directly from stool specimens collected in Cary-Blair transport media.
Cepheid announced today that it has received FDA clearance for Xpert GI Panel, a multiplex PCR test designed to provide fast ...
(Reuters) - Molecular diagnostics company Cepheid said it received a grant of up to $3.3 million, co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation, to develop ...
Cepheid (Nasdaq: CPHD) today announced it has received Emergency Use Authorization from the U.S. Food & Drug Administration (FDA) for Xpert ® Ebola, a molecular diagnostic test for Ebola Zaire Virus ...
As controversy rises over equal access to Covid-19 medical products, a manufacturer of rapid, point-of care tests is being urged to lower the price of its diagnostic and also increase sales to a World ...
Though the global number of recorded monkeypox cases continues to climb—passing 4,100 last week, according to the Centers for Disease Control and Prevention (CDC)—many researchers and epidemiologists ...
A controversy has broken out over a diagnostic for tuberculosis that, until recently, had been subsidized by the World Health Organization — the latest flare-up over access to a medical product in ...
As it transitions away from COVID-19 tests, shifting its focus back toward a range of other molecular diagnostics, Cepheid is also making some changes to its corporate makeup. For one, the ...
The organization shares the frustrations of poor countries that more cartridges weren't made available, said WHO diagnostics expert Lara Vojnov. "This is a business decision by Cepheid," she said.
(RTTNews) - Cepheid, a unit of Danaher Corp. (DHR), said Thursday that it has received a medical device license from Health Canada for Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic ...
For much of last year, the coronavirus crept, undetected, across eastern Democratic Republic of Congo. Test samples had to be sent more than 1,500 kilometres from remote hospitals to the capital ...